KW-6002 Kyowa Hakko Kogyo

Current Opinion in Investigational Drugs

Volumn 2, Issue 5, 2001, Pages 668-673

  Knutsen, L J S ^a   Weiss, S M ^a  

^a Vernalis PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 (3 CHLOROSTYRYL)CAFFEINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE A2 RECEPTOR AGONIST; APEC; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; CAFFEINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; ISTRADEFYLLINE; LEVODOPA; OXIDOPAMINE; QUINPIROLE; SKF 80723; THEOPHYLLINE; UNCLASSIFIED DRUG; WK 6002;

CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; HUMAN; PARKINSON DISEASE; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPARKINSON AGENTS; CLINICAL TRIALS; HUMANS; PARKINSON DISEASE; PURINES; RECEPTORS, PURINERGIC P1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034980425     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. 2A antagonist, on Parkinsonian models in rodents
2. 2 antagonist, (E)-1,3-dipropyl-8(3,4-dimethoxystyryl)-7-methylxanthine
3. 2 antagonists with potent anticataleptic activity
4. Roche developing new Parkinson's drug
5. Kyowa Hakko licenses anti-parkinsonism drug to Roche
6. Kyowa Hakko Kogyo Co Ltd - 1997 semiannual report
7. Boosting its sales to YEN 150 billion in 3-4 years: Mr Hirata of Kyowa Hakko Kogyo
8. Kyowa Hakko Kogyo's R & D pipeline
9. Kyowa Hakko's anti-Parkinsonism drug enters phase II in the US
10. Annual report 1999 - Kyowa Hakko Kogyo Co Ltd
11. 2A receptor antagonists as new agents for the treatment of Parkinson's disease
12. 2A) receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats
13. Phase II clinical study of an antiparkinson agent started in the USA
14. 2A receptor antagonist in MPTP-treated monkeys
15. 2A receptor in vivo
16. 2A receptors modify motor function in MPTP-treated common marmosets
17. 2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys
18. CINP 2000 - Collegium Internationale Neuro-psychopharmacologicum 22nd Congress (Part II), Brussels, Belgium
19. 2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys
20. Kyowa Hakko starts PII study on new antidepressant in US
21. 2A adenosine receptor antagonist KW-6002 treated cynomolgus monkeys
22. CINP 2000 - Collegium Internationale Neuro-psychopharmacologicum 22nd Congress (PART VI), Brussels, Belgium
23. 2A adenosine receptor antagonists - Future drugs for Parkinson's disease?
24. 2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats
25. 2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: A microdialysis study
26. 2-selective adenosine antagonists
27. 2-adenosine antagonist in vitro and in vivo
28. The effect of theophylline on Parkinsonian symptoms
29. 2A receptors and neuroprotection
30. P1 and P2 purine and pyrimidine receptor ligands
31. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
32. Glutamate and Parkinson's disease
33. 2A receptor antagonist
34. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice
35. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: A target for neuroprotection
36. 3H]-CGS 21680
37. Roche/K-Hakko halt Parkinson's deal
38. Development status of KW-6002